Pfizer Inc. $PFE Holdings Cut by Patrick Mauro Investment Advisor INC.

Patrick Mauro Investment Advisor INC. lowered its position in Pfizer Inc. (NYSE:PFE) by 54.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 186,365 shares of the biopharmaceutical company’s stock after selling 225,663 shares during the period. Pfizer accounts for 2.3% of Patrick Mauro Investment Advisor INC.’s portfolio, making the stock its 16th largest holding. Patrick Mauro Investment Advisor INC.’s holdings in Pfizer were worth $4,488,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. grew its position in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer during the 4th quarter valued at $26,000. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at $26,000. HFM Investment Advisors LLC lifted its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Global Trust Asset Management LLC boosted its holdings in Pfizer by 126.7% in the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 650 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. UBS Group reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. Guggenheim decreased their price target on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, August 7th. BMO Capital Markets lowered their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Weiss Ratings downgraded Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Stock Performance

Shares of NYSE PFE opened at $28.00 on Friday. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The company has a market cap of $159.59 billion, a P/E ratio of 36.84 and a beta of 0.34. The business’s 50 day moving average is $25.30 and its two-hundred day moving average is $26.25. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the business earned $0.78 earnings per share. Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.